ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

DOW JONES NEWSWIRES A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx. In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation. Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes. "The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement. In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations. Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year. -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
08/23/201603:03:00Deal for Medivation Is the Latest In a Line of Similar Acquisitions...
08/22/201612:52:00Pfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/10/201616:58:47Statement of Changes in Beneficial Ownership (4)
08/09/201603:03:00Botox Maker Allergan's Revenue Climbs, but Loss More Than Doubles...
08/08/201617:05:00Results from Merck’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir & g...
08/08/201616:41:16Quarterly Report (10-q)
08/08/201614:56:00Allergan Revenue Increases, Though Loss Widens--Update
08/08/201611:59:00MARKET SNAPSHOT: Stocks Retreat From Records As Health-care Stocks...
08/08/201610:20:00MARKET SNAPSHOT: Stocks Fight To Maintain Record-setting Pace...
08/08/201606:45:00REPEAT/FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Pa...
08/05/201619:30:00FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients wi...
08/05/201617:49:32Statement of Changes in Beneficial Ownership (4)
08/05/201612:58:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201610:36:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201610:15:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201609:39:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201609:20:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201609:12:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201608:00:00Merck Announces U.S. FDA Filing Acceptance of New Drug Application...
08/04/201614:30:37Statement of Changes in Beneficial Ownership (4)

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad